NCT06429891 Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
| NCT ID | NCT06429891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hua Zhu |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-08-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-08-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The symptoms of early gastric cancer are extremely insidious and most patients are identified as advanced at the time of initial diagnosis. Starting from the clinical needs, this project selects solid tumors and pathogenic glycoprotein synthesis of key glycopeptide antigen determinant mucin (MUC) family of multiple molecules as the research object. Based on the digestive system tumor research cohort established in the early stage, this project intends to verify the tumor microenvironment characteristics of the MUC family and gastric cancer treatment resistance through immunohistochemistry, COSMC gene sequencing and other technologies, and screen key MUC family proteins. Based on the discovery of differential recognition of COSMC deficient cells by antibodies, MUC1-targeted specific monoclonal antibody was developed. Further development of spatial mucinomics based on laser ablation inductively coupled plasma mass spectrometry (LA-IPC-MS) and spatial metabolome based on desorption electrospray mass spectrometry (DESI-MS) to analyze the structure and immunosuppressive mechanism of key gastric cancer glycoprotein MUC. After obtaining key targeted antibodies, with the help of biological orthogonal and click chemistry technology, the original clinical translational research based on mucin targeting was carried out, and a high-affinity nuclide conjugate drug (RDC) with "triple binding" of gastric cancer mucin was constructed and clinical translational research was carried out, which provided new ideas for the accurate diagnosis and treatment of gastric cancer in the early stage.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with solid tumor confirmed by histopathology; 3. Patients with imaging confirmed measurable lesions; 4. life expectancy \>=12 weeks. Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. ls pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refusal to join the clinical study; 5. Suffering from claustrophobia or other mental diseases； 6. Any other situation that researchers think it is not suitable to participate in the experiment.
Contact & Investigator
Hua Zhu
PRINCIPAL INVESTIGATOR
Peking University Cancer Hospital & Institute
Frequently Asked Questions
Who can join the NCT06429891 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06429891 currently recruiting?
Yes, NCT06429891 is actively recruiting participants. Contact the research team at zhuhuabch@pku.edu.cn for enrollment information.
Where is the NCT06429891 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06429891 clinical trial?
NCT06429891 is sponsored by Hua Zhu. The principal investigator is Hua Zhu at Peking University Cancer Hospital & Institute. The trial plans to enroll 50 participants.